- |||||||||| MDI-2517 / MDI Therap
A Potent Inhibitor of PAI-1, MDI-2517, Mitigates Disease Severity in Preclinical Models of Systemic Sclerosis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3580;
Based on these promising preclinical studies and standard non-clinical toxicology and safety pharmacology studies a Phase 1 first in human clinical study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of MDI-2517 is currently underway. The results of the phase 1 study will inform the continued development of MDI-2517 for the potential treatment of SSc and interstitial lung disease, and will also support the potential evaluation of MDI-2517 in other chronic fibrotic and inflammatory diseases that are associated with excessive PAI-1 activity.
|
